Berlingske
With two stock records since the New Year, Novo Nordisk’s adventure looks set to continue into 2024. The Danish pharmaceutical group is well on its way to changing the way we think about the treatment of chronic diseases and health.
With two stock records since the New Year, Novo Nordisk’s adventure looks set to continue into 2024. The Danish pharmaceutical group is well on its way to changing the way we think about the treatment of chronic diseases and health.